October 1, 2015 (Vol. 35, No. 17)

Evolving from a Gene-Based Tool Provider to a Premier Antibody Supplier, for Both Research and Diagnostic Fields

OriGene Technologies was founded in 1996 as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector.

OriGene’s mission, to prepare comprehensive sets of gene research tools and technology platforms, has enabled scientists to study complete biological pathways, thus facilitating a better understanding of biological processes and disease regulation. The comprehensive expression clone is the core asset of OriGene. Upon this foundation, the company has prepared 17,000 over-expression cell lysates, 10,000 purified recombinant human proteins from HEK293 cells, and 8,000 highly characterized TrueMAB™ monoclonal antibodies.

Over the past few years, OriGene has strategically integrated multiple technologies through corporate acquisitions to create whole-product solutions for biomedical and clinical researchers. The OriGene family now includes Cytomyx, Marligen Biosciences, and Blue Heron (a leader in gene synthesis services). The recent acquisitions of ZSbio (a leading Chinese pathology company) and SDIX mark the company’s latest venture into the anatomic pathology and IVD market.

Markets Served

1. Molecular Biology
As “Your Gene Company,” OriGene has a broad portfolio of biological reagents and services that are of value to both academic research and industry product development. Utilizing high-throughput technologies in molecular cloning, the human cDNA collection is nearing completion with respect to the NCBI RefSeq curated database of unique human transcripts. Such a comprehensive portfolio of cDNA clones is of particular value to laboratories that wish to move their projects along quickly by purchasing ready-made clones and where time is of the essence in mission critical research. If not immediately available, OriGene’s Blue Heron synthesis service can conveniently provide any gene, any sequence, in any vector, with add-on services of codon-optimization and large-scale DNA purification. With the new breakthrough of CRISPR-CAS9 technology, OriGene has quickly become a leading genome editing company, providing various vectors and gene-disruption kits for every human gene.

2. Protein Assay and Antibodies
OriGene’s 10,000 recombinant human proteins produced in human cells are of high value to researchers that are interested in authentic structure. Proteins with correct post-translational modifications (phosphorylation, glycosylation, etc.) are crucial for biologically relevant structure and functional studies. They are also ideal for assay development, small molecule interaction screening, or as antigens for antibody production.

Taking full advantage of the large collection of human proteins, OriGene has created a monthly manufacturing capacity to produce over 300 TrueMAB monoclonal antibodies. Genomic Antibody Technology, a novel antibody development platform, is also employed by OriGene to create over 1,000 antibodies against difficult targets, including multispan membrane proteins and GPCR. Such highly specific antibodies directed against authentic human protein antigens are ideal for critical assay development, especially for Flow, IP, IF, IHC, ELISA, and functional assays.

3. Diagnostic Tests
Anatomic Pathology for Oncology Biomarkers: To address the unresolved challenges of antibody cross-reactivity, OriGene has created UltraMAB™, a new class of antibodies. Each UltraMAB has been rigorously tested on OriGene’s proprietary high-density 10K protein lysate microarray to validate its mono-specificity against human protein antigens. This unmatched quality is crucial for antibody-based tests of IHC and/or flow cytometry. The launch and expansion of the UltraMAB collection have been greatly appreciated by leading diagnostic companies and antibody drug developers.

Critical Reagents for IVD: With the acquisition of SDIX, OriGene enters the IVD market as a preferred supplier of bulk critical reagents for many IVD test kits. The key products include Troponin, CRP, ALB, Strep A, and various calibrators. The accredited facilities specialize in providing bulk antibody production (in vivo and in vitro) and custom formulation.


From the largest collections of full-length cDNA clones, to human-cell produced purified proteins, from TrueMAB and UltraMAB antibodies, to IVD antibodies, OriGene has evolved from a gene-based research toolbox to a unique antibody supplier. The decade-long dedication in creating the solid foundation of TrueORF Gold clone collection, TrueMAB, 10K protein chip, UltraMAB, and Genomic Antibody Technology has positioned OriGene as an irreplaceable company for both basic and clinical researchers. For more information, contact [email protected].


9620 Medical Center Drive, Suite 200, Rockville, MD 20850
Phone: 888.267.4436
Website: www.origene.com
Date Founded: 1996
Number of Employees: 500

Previous articlePeeking Under the Hood of Cellular Signaling Machinery with Targeted Proteomics Assays
Next articleRefined Math Model May Provide Insights on Mutations Leading to Cancer